Combining a RIP1 inhibitor with Merck's hit checkpoint inhibitor Keytruda holds promise in treating pancreatic cancer, GSK says.
Capitalizing on a process the body uses to eliminate overly aggressive T cells could be a new way to treat autoimmune diseases.
Discovery made by Virginia Tech scientists on perineuronal nets could open up new approach for acquired epilepsy.
A phosphor-binding site on aberrantly spliced BRAF V600E could become a new target against drug-resistant melanoma.
Using broadly neutralizing single-domain antibodies from llamas, scientists have designed a vaccine that can potentially combat almost all flu viruses.
Scientists at Vanderbilt University found that a glutaminase inhibitor improved the anticancer activity of CAR-T cells.
Roche’s Rituxan and an anti-CD47 drug from Stanford shrank the cancers of half the patients in a phase 1 trial.
Protein clumps that occur in both the gut and the brain could be prime targets for Parkinson's therapies, new research suggests.
Chemotherapy sparks a "kill code” in cancer cells, but Northwestern scientists may have found a better way to trigger it.
In mouse models of obesity, the naturally occurring protein FGFBP3 drastically reduced fat mass.
